At a glance
- Company
- Adherium Limited
- Ticker
- ASX: ASX:ADR
- Announcement
- Partnership
- Location
- Melbourne, Australia
Key figures
- Contract value
- $1.1M
- Contract duration
- three years
People
- Dr. Paul MastoridisCEO
Products and programs
Melbourne, Australia, May 24, 2024 -- Adherium Limited (“Adherium” or “the Company”; ASX:ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that AstraZeneca has selected its Hailie® Smartinhaler® platform for a clinical trial. This contract is valued at $1.1M over the course of three years.
AstraZeneca’s inhaled medication use will be recorded and transferred via Hailie Smartinhaler devices.
Adherium CEO, Dr. Paul Mastoridis, said: “This agreement underscores Adherium's strategic commitment to enhancing patient care through advanced technology. Our Hailie® platform is designed to ensure precise monitoring and support for patients with respiratory diseases, facilitating the pursuit of tailored therapy."
Adherium will be providing Hailie® Smartinhalers®, Hailie® app and Platform for the trial, allowing for accurate tracking of inhaler medication use through the selected eCOA (Electronic Clinical Outcome Assessment) devices.
If you detect any issues, problems, or errors in this press release content, kindly contact [email protected] to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.
Questions around this news
What was AstraZeneca’s agreement with Adherium for?
The release says AstraZeneca selected Adherium’s Hailie Smartinhaler platform for a clinical trial. Adherium will provide Smartinhalers, its app and platform, enabling inhaler medication use to be tracked through selected electronic clinical outcome assessment devices. The announcement does not identify the trial’s condition, patient population or study design.
What is the stated value and duration of the contract?
The release values the contract at $1.1 million over three years. It does not provide further details about payment timing, the allocation of the contract value, or whether the agreement includes options to extend or expand the work.
What information will the Smartinhaler devices record for the trial?
According to the release, the devices will record use of AstraZeneca’s inhaled medication, and that information will be transferred through the Hailie platform. Adherium says the tracking will take place through selected electronic clinical outcome assessment devices. The release does not specify which medication or what additional data will be collected.
What is an electronic clinical outcome assessment (eCOA)?
An eCOA is a digital method for collecting information about a participant’s health or experience in a clinical study. Depending on the study, information may be entered by participants, clinicians or caregivers, or captured through connected devices. Researchers use these assessments to evaluate outcomes according to the study’s methods.
Earlier from Adherium Limited
- Adherium Partners with Rimidi to Revolutionise Respiratory Clinical Management Solutions
- First Patient Enrolled Major e-health Respiratory Management Clinical Study
- Adherium Partners with NuvoAir Medical to Enhance Patient Outcomes
- Adherium Commences Production and US Market Release of Advanced Teva pMDI Compatible Smartinhaler
- First Patients Enrolled at SENTA Partners in the US
